First Week of March 20th Options Trading For AtriCure (ATRC)

AtriCure (ATRC) option ideas: a $35 put is trading with a $0.10 bid implying a net cost basis of $34.90 versus the stock at $37.18 (≈6% out-of-the-money) with a 67% probability of expiring worthless and a 0.29% return (2.37% annualized) if it does. On the call side, a $40 covered call with a $0.10 bid represents an ≈8% upside and would yield a 7.85% total return if called at the March 20 expiration; the probability the call expires worthless is ~55%, equating to a 0.27% boost (2.23% annualized). Implied volatility is 77% on the put and 64% on the call versus a trailing 12-month volatility of 48%, highlighting elevated option premiums relative to historical stock volatility.

Analysis

Market structure: The immediate winners are short-dated premium sellers and investors willing to be long at a discount (cash‑secured put sellers targeting an effective entry of $34.90 vs current $37.18). The put/call IV skew (puts 77% vs calls 64% vs realized 48%) signals higher demand for downside protection—market pricing tilts toward guarding vs chasing upside, which concentrates risk-premia into option sellers and liquidity providers.

Risk assessment: Tail risks include an FDA/regulatory setback or device/quality issue that could generate >30% downside in days and spike IV >100% (high-impact, low-probability). Near-term (days–weeks) option positions will be dominated by time decay and IV moves; medium-term (months) fundamentals—procedure volumes, reimbursement—drive equity direction; long-term (quarters–years) depends on product adoption and M&A appetite. Hidden dependencies: reimbursement cycles, hospital procurement budgets, and single-study readouts can flip sentiment quickly.

Trade implications: Given IV>realized, prefer defined‑risk premium-selling: cash‑secured puts or bull‑put spreads into Mar 20 expiry to harvest ~0.27–0.29% per cycle (2.2–2.4% annualized) while capping downside. For directional conviction, buy equity up to 2% portfolio and sell the Mar 20 $40 call (caps upside at 7.85%) or use a 35/32.5 bull‑put spread to limit max loss to $2.50/share. Avoid outright long vega until a clear catalyst; instead buy short protection if assigned.

Contrarian angles: The market may be overpricing tail downside in short-dated options—puts richer than calls—creating asymmetric entry opportunities for disciplined cash‑secured sellers who accept assignment risk. Historical small‑cap medtech patterns show steep drawdowns followed by recoveries; however, owning post‑assignment exposes you to binary regulatory events, so cap position sizes (<=2% portfolio) and use defined‑risk structures.

Key Decisions for Investors

• Sell ATRC Mar 20 2026 $35 cash‑secured put at $0.10 (sell-to-open) size to limit max assignment to ≤2% portfolio equity; target net entry $34.90; set buy-to-close if ATRC trades below $32.50 or mark-to-market loss exceeds 150% of premium.
• If comfortable owning stock, establish up to a 2% portfolio long in ATRC at current $37.18 and sell the Mar 20 $40 covered call for $0.10 (collecting ~0.27% boost; 7.85% total capped upside); stop-loss at -18% (~$30.50) or roll calls if ATRC > $40 prior to expiry.
• Implement a defined-risk bull‑put spread: sell Mar 20 $35 put and buy Mar 20 $32.50 put to cap downside to $2.50/share; target net credit ≥ $0.08 and keep position size so max loss ≤2% portfolio; this harvests skew premium while limiting tail exposure.
• Do not buy long‑dated ATRC vol now; instead allocate a 0.5–1% tactical allocation to buy short protection (buy one ITM or ATM put) only if an upcoming catalyst (FDA/earnings within 30–60 days) raises event risk—protect positions if IV spikes above 100% or share price gaps >20% intraday.